N/A N=47 Estimating Apnea Phenotypes From Polysomnography: Oxygen
Sleep Apnea
Primary: Apnea-hypopnea Index — 40.5; 57.9; 48.5; 74.3 events/hour — p=0.4
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=510 Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
Macular Degeneration
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS)…
Phase 1 N=54 A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
Neoplasm, Advanced or Metastatic
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-117 — 4632.992; 6225.347; 6455.111; 7847.591 nanogram per milliliter (ng/mL)
Phase 2 N=92 The Spot Sign for Predicting and Treating ICH Growth Study
Intracerebral Hemorrhage
Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00
Phase 2 N=42 Abiraterone Post Ketoconazole for Prostate Cancer
Prostate Cancer
Primary: Preliminary Evidence of Efficacy of Abiraterone Acetate — 20 Participants
Phase 4 N=28 U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne
Acne Vulgaris
Primary: Mean Percent Change in Inflammatory, Non Inflammatory, and Total Lesion Counts From Baseline to Week 8 — -62.1; -49.8; -56.9 Percent change
Phase 2 N=194 Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Primary: Progression Free Survival (PFS) — 6.86; 13.00 weeks — p=0.0022
Phase 2 N=127 Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer
Ovarian Cancer
Primary: Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis — 5; 130; 50 Modified H-Score — p=0.012
Phase 2 N=40 A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients
Phase 3 N=4,804 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic…
Phase 4 N=54 Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression — 10.79; 15.30; 12.75 units on a scale
Phase 4 N=15 52 Week Trial of Liraglutide in Type 1 Diabetes
Type 1 Diabetes
Primary: Assessment of Changes in Glycemic Control by HbA1c. — 0.3; 0.2 percentage of HbA1c
Phase 2 N=12 Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia
Encephalopathy, Hypoxic-Ischemic
Primary: Steady State Clonidine Blood Levels During Hypothermia — 0.6 ng/ml
N/A N=53 Intervention for IPV Perinatal Women- RCT
Intimate Partner Violence
Primary: Composite Abuse Scale (CAS)-CAS Victimization Total Score — 26.36; 16.56; 12.38; 16.52 units on a scale — p=0.4016
Phase 2 N=3 An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Mucopolysaccharidosis Type 7
Primary: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate — -50.41; -38.94; -63.49; -51.82 percentage change